HIPPURAN I 131 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hippuran I 131, and what generic alternatives are available?
Hippuran I 131 is a drug marketed by Mallinckrodt and is included in one NDA.
The generic ingredient in HIPPURAN I 131 is iodohippurate sodium i-131. Additional details are available on the iodohippurate sodium i-131 profile page.
Summary for HIPPURAN I 131
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 4 |
Clinical Trials: | 2 |
Patent Applications: | 95 |
Formulation / Manufacturing: | see details |
DailyMed Link: | HIPPURAN I 131 at DailyMed |
Recent Clinical Trials for HIPPURAN I 131
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Rigshospitalet, Denmark | Phase 1 |
University of Copenhagen | Phase 1 |
University Medical Center Groningen | Phase 2 |
US Patents and Regulatory Information for HIPPURAN I 131
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mallinckrodt | HIPPURAN I 131 | iodohippurate sodium i-131 | INJECTABLE;INJECTION | 016666-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |